These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 24471304)

  • 1. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
    Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Technical specifications for post-marketing pharmacoeconomic evaluation of Chinese medicine (draft version for comments)].
    Xie YM; Wang X; Wang N; Chang YP
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2925-9. PubMed ID: 24471305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expert consensus post-marketing evaluation scheme to detect immunotoxicity of Chinese medicine in clinical populations (draft version for comments)].
    Xie YM; Zhao YB; Jiang JJ; Chang YP; Zhang W; Shen H; Lu PF
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2933-6. PubMed ID: 24471307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Establishment of model of traditional Chinese medicine injections post-marketing safety monitoring].
    Guo XE; Zhao YB; Xie YM; Zhao LC; Li YF; Hao Z
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2974-8. PubMed ID: 24471314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance].
    Zhang W; Xie YM; Yu WY
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expert consensus for postmarketing Chinese medicine intensive hospital safety monitoring.
    Liao X; Zhang W; Xie YM; Tian F; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W
    Chin J Integr Med; 2014 Jul; ():. PubMed ID: 24993333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
    Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
    Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-marketing safety surveillance and re-evaluation of Xueshuantong injection.
    Li C; Xu T; Zhou P; Zhang J; Guan G; Zhang H; Ling X; Li W; Meng F; Liu G; Lv L; Yuan J; Li X; Zhu M
    BMC Complement Altern Med; 2018 Oct; 18(1):277. PubMed ID: 30326892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of the Xuesaitong injection in China: results from a large-scale multicentre post-marketing surveillance study in a real-world setting.
    He Y; Gao XM; Li L; Liu XG; Liu W; Hong XJ; Huang BH; Yang HL; Xue MH; Wu XJ; Liu JF
    Curr Med Res Opin; 2020 Dec; 36(12):1947-1953. PubMed ID: 33016133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Enlightenment of adverse reaction monitoring on safety evaluation of traditional Chinese medicines].
    Song HB; Du XX; Ren JT; Yang L; Guo XX; Pang Y
    Zhongguo Zhong Yao Za Zhi; 2015 Apr; 40(8):1620-3. PubMed ID: 26281610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Technical specifications for hospital-based intensive monitoring of post-marketing Chinese patent medicine].
    Xie YM; Liao X; Jiang JJ; Zhang YL; Ma R; Zhu MJ; Zhan SY; Liu JP; Liu J; Wen ZH; Yang ZQ; He Y; Li XL
    Zhongguo Zhong Yao Za Zhi; 2019 Jul; 44(14):2896-2901. PubMed ID: 31602831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on 10 409 cases of post-marketing safety Danhong injection centralized monitoring of hospital].
    Li X; Tang J; Meng F; Li C; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2783-5. PubMed ID: 22292364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Technical specifications for rational clinical use of parenterally administered Chinese medicine (draft version for comments)].
    Xie YM; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Zhao YB
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2930-2. PubMed ID: 24471306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of rational clinical uses of traditional Chinese medicine injections and factors influencing adverse drug reactions].
    Sun SG; Li ZF; Xie YM; Liu J; Lu Y; Song YF; Han YH; Liu LD; Peng TT
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2969-73. PubMed ID: 24471313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison and analysis of clinical safety evaluation methods for parenterally administered Chinese medicine].
    Yan BH; Peng C; Xie YM; Wang YY
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2979-82. PubMed ID: 24471315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China.
    Li J; Li M; Li L; Ma L; Cao A; Wen A; Chen W; Li L; Liang Y; Deng J
    BMC Pharmacol Toxicol; 2022 Jul; 23(1):51. PubMed ID: 35842685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thought on several problems of clinical revaluation of post-marketing herb research].
    He W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(12):1641-3. PubMed ID: 20815225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-marketing safety monitoring of shenqifuzheng injection: a solution made of dangshen (Radix Codonopsis) and huangqi (Radix Astragali Mongolici).
    Ai Q; Zhang W; Xie Y; Huang W; Liang H; Cao H
    J Tradit Chin Med; 2014 Aug; 34(4):498-503. PubMed ID: 25185371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Establish research model of post-marketing clinical safety evaluation for Chinese patent medicine].
    Zheng WK; Liu Z; Lei X; Tian R; Zheng R; Li N; Ren JT; Du XX; Shang HC
    Zhongguo Zhong Yao Za Zhi; 2015 Sep; 40(18):3693-6. PubMed ID: 26983223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening].
    Yang W; Xiang YY; Xie YM; Shen H
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3013-8. PubMed ID: 24471322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.